COVID-19 is an emerging, rapidly evolving situation.
Get the latest information from CDC (Coronavirus.gov) | NIH Resources | NIDA Resources
Related Funding Opportunities
Supplemental information for PAR-16-357
Office of the Director
Program Announcements
- NIDA Program Project Grant Applications (Clinical Trial Optional) - PAR-19-345 (P01)
- NIDA Research Education Program for Clinical Researchers and Clinicians (Clinical Trial Not Allowed) - PAR-19-258 (R25)
- NIDA Research Center of Excellence Grant Program (Clinical Trial Optional) - PAR-19-259 (P50)
- Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (Clinical Trial Not Allowed) - PA-18-876 (R01)
Notices
Chemistry Pharmacology Branch
Program Announcements
- Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (Clinical Trial Not Allowed) - PAR-19-039 (U01)
- Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (Clinical Trial Optional) - PAR-19-040 (U01)
- BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR) (Clinical Trials Not Allowed) - PA-18-870 (R41/R42)
- BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR) (Clinical Trial Not Allowed) - PA-18-871 (R43/R44)
- Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (Clinical Trial Optional) - PAR-18-657 (U54)
- Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (Clinical Trial Optional) - PAR-18-527 (R03)
- Assay development and screening for discovery of chemical probes or therapeutic agents - PAR-17-438 (R01)
- Discovery of in vivo Chemical Probes for Novel Brain Targets - PAR-17-336 (R01)
Notices
Genetics, Epigenetics and Development Branch
Request for Applications
Program Announcements
- Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (Basic Experimental Studies with Humans Required) - PAR-19-384 (R01)
- Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (Clinical Trial Not Allowed) - PAR-19-278 (R21/R33)
- Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (Clinical Trial Optional) - PAR-19-223 (DP1)
- AIDS-Science Track Award for Research Transition (Clinical Trial Optional) - PA-18-916 (R03)
- Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (Clinical Trial Optional) - PA-18-917 (R01)
- HIV/AIDS High Priority Drug Abuse Research (Clinical Trial Optional) - PAS-18-915 (R01)
- Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (Clinical Trial Not Allowed) - PAR-18-789 (U01)
- Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (Clinical Trial Optional) - PAR-18-742 (R61/R33)
- Cutting-Edge Basic Research Awards (CEBRA) (Clinical Trial Optional) - PAR-18-437 (R21)
- NIDA Core "Center of Excellence" Grant Program (Clinical Trial Optional) - PAR-18-225 (P30)
- Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders - PA-17-155 (R01)
- Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders - PA-17-157 (R21)
- Basic Mechanisms of Brain Development Mediating Substance Use and Dependence - PA-17-119 (R01)
- Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities - PA-17-120 (R01)
Notices
Behavioral Cognitive Neuroscience Branch
Request for Applications
- The Intersection of Sex and Gender Influences on Health and Disease (Clinical Trial Optional) - RFA-OD-19-029 (R01)
- Tobacco Regulatory Science (Clinical Trial Optional) - RFA-OD-19-028 (R01)
- Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research (Clinical Trial Not Allowed) - RFA-OD-19-021 (R21)
- Secondary Analyses of Existing Datasets of Tobacco Use and Health (Clinical Trial Not Allowed) - RFA-OD-19-022 (R21)
Program Announcements
- Behavioral Science Track Award for Rapid Transition (B/Start) (Clinical Trial Optional) - PAR-19-310 (R03)
- Exploratory Clinical Neuroscience Research on Substance Use Disorders (Clinical Trial Optional) - PAR-19-282 (R61/R33)
- Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (Clinical Trial Optional) - PA-19-200 (R01)
- Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (Clinical Trial Optional) - PA-19-201 (R21)
- Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (Clinical Trial Not Allowed) - PAR-19-163 (R21)
- Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (Clinical Trial Not Allowed) - PAR-19-162 (R01)
- Imaging - Science Track Award for Research Transition (I/START) (Clinical Trial Optional) - PAR-18-918 (R03)
- Mechanistic investigations of psychosocial stress effects on opioid use patterns (Clinical Trial Optional) - PAS-18-625 (R21)
- Mechanistic investigations of psychosocial stress effects on opioid use patterns (Clinical Trial Optional) - PAS-18-624 (R01)
- Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (Clinical Trial Optional) - PA-18-603 (R01)
- Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Clinical Trial Not Allowed ) - PA-18-592 (Admin Supp)
- Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (Clinical Trial Optional) - PAR-18-509 (R21)
- Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (Clinical Trial Optional) - PAR-18-510 (R01)
- Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (Clinical Trial Optional) - PAR-18-227 (R01)
Notices
- Notice of Additional Funds Available for PAS-18-624, "Mechanistic investigations of psychosocial stress effects on opioid use patterns (R01- Clinical Trial Optional)" - NOT-DA-18-048
- Notice of Additional Funds Available for PAS-18-625, " Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional)" - NOT-DA-18-049
Integrative Neuroscience Branch
Program Announcements
- NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (Clinical Trial Optional) - PAR-18-746 (K12)
- Neuroscience Research on Drug Abuse (Clinical Trial Optional) - PA-18-060 (R01)
- Neuroscience Research on Drug Abuse (Clinical Trial Optional) - PA-18-078 (R21)
- Imaging the Persistent HIV Reservoir - PA-17-305 (R01)
- HIV-1 infection of the Central Nervous System - PA-17-100 (R01)
Notices
- BRAIN Initiative: Notice of Support for Research on the Fundamental Neurobiology of Endogenous Opioid Systems - NOT-DA-18-046
- Notice of Change to the Open Date in PA-18-917, "Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment" (R01 - Clinical Trial Optional) - NOT-DA-18-044
- Notice of Change to the Eligibility of Foreign Components in PA-18-060, " Neuroscience Research on Drug Abuse (R01)" - NOT-DA-18-042
- Notice of Change to the Eligibility of Foreign Components in PA-18-078, " Neuroscience Research on Drug Abuse (R21)" - NOT-DA-18-043